Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Terminated 8Recruiting 8Completed 7Unknown 5Withdrawn 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 10Recurrence 5Leukemia, Myelomonocytic, Chronic 4Leukemia 4Lymphoma, T-Cell, Peripheral 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Hematologic Neoplasms 2Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myeloid 1Glioma 1Frailty 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 11Rituximab 10Gemcitabine 9Paclitaxel 7Lenalidomide 7Decitabine 7Cytarabine 7Bendamustine Hydrochloride 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Carboplatin 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Antilymphocyte Serum 4tislelizumab 3pomalidomide 3liposomal doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Recurrence × Azacitidine × Clear all
NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The First Affiliated Hospital of Soochow University

Phase NA Unknown
20 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT04809181 2023-02-21

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
95 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT04913922 2022-11-08

AARON

Ludwig-Maximilians - University of Munich

Phase 2 Unknown
30 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1/2 Unknown
13 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML

The First Affiliated Hospital of Soochow University

Phase 3 Unknown
30 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡